Invesco Biotechnology & Genome ETF
PBENYSEARCAInvescoEquity
As of Oct 16, 2026 close
- Assets (AUM)
- $424.35M
- Expense ratio
- 0.59%
- Dividend yield
- 1.35%
- Holdings
- 33
- 52-week range
- $70.83$98.82
- Volume (live)
- -
- Avg. volume (3M)
- 12.08K
PBE ETF: Invesco Biotechnology & Genome ETF - Price, Holdings & Analysis
Invesco Biotechnology & Genome ETF Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fund characteristics, expense ratio, dividend yield, and performance metrics
| Day's Range | $95.93 - $98.27 |
|---|---|
| 52-Week High | $98.82 |
| 52-Week Low | $70.83 |
| Open | $98.27 |
| Volume (last close) | 11.16K |
| Average Volume (3M) | 12.08K |
| 1 Day Change | +2.00% |
|---|---|
| 1 Month Change | +3.11% |
| 6 Month Change | +20.49% |
| YTD Change | +19.80% |
| 1 Year Change | +36.58% |
| 5 Year Change | +32.47% |
| 10 Year Change | +155.41% |
| Annual Dividend | $1.33 |
|---|---|
| Dividend Yield | 1.35% |
| Last Dividend Ex-Date | Sep 21, 2026 |
| Dividend Growth YoY | +234.02% |
| Years Dividend Growth | 2 |
| Assets (AUM) | $424.35M |
|---|---|
| Expense Ratio | 0.59% |
| Total Holdings | 33 |
| Inception Date | Jun 22, 2005 |
| 50-Day MA | $95.67 |
|---|---|
| 200-Day MA | $86.24 |
| RSI | 53.49 |
| Stochastic %K | 74.53 |
| Stochastic %D | 60.88 |
Source: Exchange price data and fund disclosures. Data as of Oct 16, 2026. Data sources and methodology
PBE at a Glance
Invesco Biotechnology & Genome ETF (PBE) is an equity ETF from Invesco, launched in June 2005. It manages $424.35M in assets and charges a 0.59% expense ratio, about $59 a year per $10,000 invested.
As of its Oct 4, 2026 holdings, it holds 33 positions. The largest are Natera, Inc. (NTRA, 6.31%), Illumina, Inc. (ILMN, 6.29%) and Biogen Inc (BIIB, 5.18%). The top 10 holdings make up 49.2% of the fund. By sector it leans toward Healthcare (100.0%). 100.0% of assets are in the United States.
It pays distributions yielding 1.35% at the Oct 16, 2026 close, $1.33 per share over the trailing 12 months. As of the Oct 16, 2026 close, the share price is up 36.6% over one year, up 32.5% over five years and up 155.4% over ten years (price change, excluding distributions).
Frequently Asked Questions About Invesco Biotechnology & Genome ETF
What is the current price of PBE?
The latest PBE price is $96.08 (Oct 16, 2026 close). The 52-week range is $70.83–$98.82. The share price is up 36.6% over the past year (price change, excluding distributions).
What is the expense ratio for PBE?
PBE's annual expense ratio is 0.59%. This represents the yearly cost of holding the fund, deducted from total returns. Compare with similar Equity ETFs in the ETF Screener.
Does PBE pay dividends?
Yes, PBE pays a 1.35% dividend yield (trailing 12 months, at the Oct 16, 2026 close). The most recent ex-dividend date was September 21, 2026. View full dividend history in the Dividends section.
What are the top holdings of PBE?
As of Oct 4, 2026, PBE's largest holdings are Natera, Inc. (6.3%), Illumina, Inc. (6.3%), Biogen Inc (5.2%) (combined weight: 17.8%). The fund holds 33 total positions. View the complete portfolio breakdown in the Holdings section.
How does PBE compare to similar ETFs?
Compare PBE (0.59% expense ratio, $424M AUM) against similar Equity ETFs using the ETF Screener. Filter by expense ratio, dividend yield, and performance to find alternatives.